Fibrates for secondary prevention of cardiovascular disease and stroke.
CONCLUSIONS: Moderate evidence showed that the fibrate class can be effective in the secondary prevention of composite outcome of non-fatal stroke, non-fatal MI, and vascular death. However, this beneficial effect relies on the inclusion of clofibrate data, a drug that was discontinued in 2002 due to its unacceptably large adverse effects. Further trials of the use of fibrates in populations with previous stroke and also against a background treatment with statins (standard of care) are required.
PMID: 26497361 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Wang D, Liu B, Tao W, Hao Z, Liu M Tags: Cochrane Database Syst Rev Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Conferences | Coronary Heart Disease | Databases & Libraries | Diabetes | Diabetes Mellitus | Endocrinology | Fenofibrate | Gemfibrozil | General Medicine | Heart | Heart Attack | Heart Disease | Laboratory Medicine | Science | Statin Therapy | Stroke | Study | Tricor